Malaria vaccine
AssigneeNew York University
InventorsRuth S. Nussenzweig, G. Nigel Godson, Victor Nussenzweig
Life of this patent
Estimating the term…
Abstract
The present invention provides antisera and monoclonal antibodies directed against the sporozoite stage of the malaria parasite capable of providing protection against infection in both animals and humans. The invention further provides a purified antigen derived from sporozoites of the malaria parasite, the antigen being suitable for use as a vaccine against malarial infections in both animals and humans. The invention further provides means for preparing said antigen and a vaccine comprising said antigen.
Claims5
An antigenic protein consisting essentially of a sporozoite polypeptide selected from the group consisting of Pb-44, derived from Plasmodium berghei;
- Pk-44, derived from Plasmodium knowlesi;
- Pf-44, derived from Plasmodium falciparum;
- and Pv-44, derived from Plasmodium vivax;
- in purified form.
Dependencies are inferred from the claim text.